Thompson G Marie, Trainor Deirdre, Biswas Chhabi, LaCerte Carl, Berger Joel P, Kelly Linda J
Department of Metabolic Disorders, Merck Research Laboratories, 126 E Lincoln Ave., Rahway, NJ 07065, USA.
Anal Biochem. 2004 Jul 1;330(1):21-8. doi: 10.1016/j.ab.2004.03.061.
A novel class of insulin-sensitizing agents, the thiazolidinedines (TZDs), has proven effective in the treatment of type 2 diabetes. These compounds, as well as a subclass of non-TZD insulin-sensitizing agents, have been shown to be peroxisome proliferator-activated receptor (PPAR) gamma agonists. PPARgamma plays a critical role in adipogenesis and PPARgamma agonists have been shown to induce adipocyte differentiation. Here, PPARgamma ligand activity has been assessed in murine 3T3-L1 cells, a commonly used in vitro model of adipogenesis, by measuring their ability to induce adipocyte fatty acid-binding protein (aP2) mRNA expression. In order to perform this task, we have developed a novel, multiwell assay for the direct detection of aP2 mRNA in cell lysates that is based on hybridization of mRNA to target-specific oligonucleotides. These oligonucleotide probes are conjugated to enzymes that efficiently process unique chemical substrates into robust fluorescent products. Ribosomal protein 36B4 mRNA, a gene whose expression is unaffected by adipogenesis, serves as the control in the assay. Two assay formats have been developed, a single analyte assay in which aP2 and 36B4 mRNA expression are assayed in separate lysate aliquots and a dual analyte assay which can measure aP2 and 36B4 mRNA simultaneously. Both forms of the assay have been used to quantify attomole levels of aP2 and 36B4 mRNAs in differentiating 3T3-L1 preadipocytes treated with PPARgamma agonists. The potencies of PPARgamma agonists determined by this novel methodology showed good correlation with those derived from aP2 mRNA slot-blot analysis and PPARgamma transactivation assays. We conclude that the aP2 single and dual analyte assays both provide specific and sensitive measurements of endogenous aP2 mRNA levels that can be used to assess the activity of PPARgamma ligands in 3T3-L1 cells. Since the assay obviates the need for RNA isolation and is performed in an automatable multiwell format, it can serve as a high-throughput, cell-based screen for the identification and characterization of PPARgamma modulators.
一类新型的胰岛素增敏剂——噻唑烷二酮类(TZDs)已被证明在治疗2型糖尿病方面有效。这些化合物以及非噻唑烷二酮类胰岛素增敏剂的一个亚类已被证明是过氧化物酶体增殖物激活受体(PPAR)γ激动剂。PPARγ在脂肪生成中起关键作用,并且PPARγ激动剂已被证明可诱导脂肪细胞分化。在此,通过测量其诱导脂肪细胞脂肪酸结合蛋白(aP2)mRNA表达的能力,在小鼠3T3-L1细胞(一种常用的脂肪生成体外模型)中评估了PPARγ配体活性。为了执行此任务,我们开发了一种新颖的多孔测定法,用于直接检测细胞裂解物中的aP2 mRNA,该方法基于mRNA与靶标特异性寡核苷酸的杂交。这些寡核苷酸探针与能够将独特的化学底物有效加工成强荧光产物的酶偶联。核糖体蛋白36B4 mRNA是一种其表达不受脂肪生成影响的基因,用作该测定中的对照。已开发出两种测定形式,一种是单分析物测定法,其中在单独的裂解物等分试样中测定aP2和36B4 mRNA表达,另一种是双分析物测定法,可同时测量aP2和36B4 mRNA。这两种测定形式均已用于定量在用PPARγ激动剂处理的分化中的3T3-L1前脂肪细胞中aP2和36B4 mRNA的阿托摩尔水平。通过这种新方法确定的PPARγ激动剂的效力与源自aP2 mRNA狭缝印迹分析和PPARγ反式激活测定的效力显示出良好的相关性。我们得出结论,aP2单分析物和双分析物测定均提供了内源性aP2 mRNA水平的特异性和灵敏测量,可用于评估3T3-L1细胞中PPARγ配体的活性。由于该测定无需进行RNA分离且以可自动化的多孔形式进行,因此它可作为一种高通量的基于细胞的筛选方法,用于鉴定和表征PPARγ调节剂。